Vaccinex Company Insiders
| VCNX Stock | USD 1.13 0.05 4.63% |
Vaccinex employs about 37 people. The company is managed by 7 executives with a total tenure of roughly 87 years, averaging almost 12.0 years of service per executive, having 5.29 employees per reported executive. Break down of Vaccinex's management performance can provide insight into the company performance.
| Jill CPA Executive Chief Officer |
| Jill Sanchez Executive Interim Controller |
Vaccinex |
Vaccinex Management Team Effectiveness
The company has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities.Over half of Vaccinex's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions.
Some institutional investors establish a significant position in pink sheets such as Vaccinex in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Vaccinex, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Vaccinex Workforce Comparison
Vaccinex is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,247. Vaccinex holds roughly 37.0 in number of employees claiming about 2.97% of equities under Health Care industry.
Vaccinex Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccinex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccinex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vaccinex insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Maurice Zauderer over a year ago Acquisition by Maurice Zauderer of 1877 shares of Vaccinex at 8.21 subject to Rule 16b-3 | ||
Van Strydonck, Gerald E. over a year ago Disposition of 3149 shares by Van Strydonck, Gerald E. of Vaccinex at 0.72 subject to Rule 16b-3 | ||
Maurice Zauderer over a year ago Acquisition by Maurice Zauderer of 46153 shares of Vaccinex at 3.25 subject to Rule 16b-3 | ||
Elizabeth Evans over a year ago Acquisition by Elizabeth Evans of 1341 shares of Vaccinex at 8.21 subject to Rule 16b-3 | ||
Jill Sanchez over a year ago Disposition of tradable shares by Jill Sanchez of Vaccinex at 615.3 subject to Rule 16b-3 | ||
Friedberg Albert over a year ago Acquisition by Friedberg Albert of 6711552 shares of Vaccinex at 0.3743 subject to Rule 16b-3 | ||
Friedberg Albert over a year ago Acquisition by Friedberg Albert of 100 shares of Vaccinex at 4.51 subject to Rule 16b-3 | ||
Friedberg Albert over a year ago Acquisition by Friedberg Albert of 2753 shares of Vaccinex at 4.92 subject to Rule 16b-3 |
Vaccinex Notable Stakeholders
A Vaccinex stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaccinex often face trade-offs trying to please all of them. Vaccinex's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaccinex's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jill CPA | Chief Officer | Profile | |
| Jill Sanchez | Interim Controller | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ernest Smith | Senior Officer | Profile | |
| Maurice Zauderer | CEO, CoFounder | Profile | |
| Elizabeth Evans | COO Medicine | Profile | |
| John Leonard | Senior Development | Profile |
About Vaccinex Management Performance
The success or failure of an entity such as Vaccinex often depends on how effective the management is. Vaccinex management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaccinex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaccinex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D . Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. Vaccinex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Please note, the imprecision that can be found in Vaccinex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaccinex. Check Vaccinex's Beneish M Score to see the likelihood of Vaccinex's management manipulating its earnings.
Vaccinex Workforce Analysis
Traditionally, organizations such as Vaccinex use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaccinex within its industry.Vaccinex Manpower Efficiency
Return on Vaccinex Manpower
| Revenue Per Employee | 15.4K | |
| Revenue Per Executive | 81.4K | |
| Net Loss Per Employee | 547.3K | |
| Net Loss Per Executive | 2.9M |
Additional Tools for Vaccinex Pink Sheet Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.